Aquestive Therapeutics (AQST) Return on Capital Employed (2018 - 2026)

Aquestive Therapeutics' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 46.96% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 234.0% year-over-year to 46.96% in Q1 2026; TTM through Mar 2026 was 46.96%, a 234.0% increase from a year earlier, with the FY2025 full-year figure at 85.28%, down 3446.0% from the prior year.
• Return on Capital Employed grew to 46.96% in Q1 2026 per AQST's latest filing, from 62.12% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 13.85% in Q2 2024 and bottomed at 281.76% in Q4 2022.
• The 5-year median for Return on Capital Employed is 62.12% (2025), against an average of 94.3%.
• Across the five-year window, Return on Capital Employed sank 19856 bps in 2022 and soared 24413 bps in 2023, its largest moves.
• Year by year, Return on Capital Employed stood at 281.76% in 2022, then surged by 87 bps to 37.64% in 2023, then gained by 6 bps to 35.44% in 2024, then sank by 75 bps to 62.12% in 2025, then grew by 24 bps to 46.96% in 2026.
• Per Business Quant, the three latest AQST Return on Capital Employed figures stand at 46.96% (Q1 2026), 62.12% (Q4 2025), and 54.14% (Q3 2025).